Table 2.
Associations (β-Estimates) of Sex-Specific Quartiles of Baseline Plasma FGF23 Concentrations With Total Hip BMDa
| Quartiles |
Per Doubling of FGF23 | ||||
|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | ||
| Women | |||||
| FGF23, RU/mL | <56.2 | 56.2–74.5 | 74.5–106.5 | >106.5 | |
| Unadjusted | 1.00 (Reference) | −0.01 (−0.04 to 0.02) | 0.01 (−0.01 to 0.04) | 0.02 (−0.01 to 0.05) | 0.01b (0.001–0.03) |
| Model 1 | 1.00 (Reference) | 0.004 (−0.02 to 0.03) | 0.04b (0.01–0.06) | 0.04b (0.01–0.07) | 0.02b (0.01–0.03) |
| Model 2 | 1.00 (Reference) | −0.01 (−0.03 to 0.02) | 0.02 (−0.01 to 0.04) | 0.02 (−0.01 to 0.04) | 0.01 (−0.001 to 0.02) |
| Model 3 | 1.00 (Reference) | −0.002 (−0.03 to 0.02) | 0.02 (−0.01 to 0.04) | 0.02 (−0.01 to 0.05) | 0.01 (0–0.02) |
| Men | |||||
| FGF23 (RU/mL) | <51.8 | 51.8–66.4 | 66.4–92.1 | >92.1 | |
| Unadjusted | 1.00 (Reference) | 0.002 (−0.04 to 0.04) | 0.03 (−0.004 to 0.07) | 0.01 (−0.03 to 0.04) | 0.001 (−0.02 to 0.02) |
| Model 1 | 1.00 (Reference) | 0.01 (−0.03 to 0.05) | 0.06b (0.02–0.10) | 0.04b (0.003–0.08) | 0.01 (−0.002 to 0.03) |
| Model 2 | 1.00 (Reference) | 0.01 (−0.02 to 0.04) | 0.05b (0.02–0.09) | 0.03 (−0.01 to 0.06) | 0.02 (−0.001 to 0.03) |
| Model 3 | 1.00 (Reference) | 0.01 (−0.03 to 0.04) | 0.05b (0.02–0.09) | 0.03 (−0.01 to 0.07) | 0.02b (0.001–0.04) |
a
Total hip BMD was measured approximately 2 years before FGF23 concentration was obtained. Model 1 is adjusted for age and race. Model 2 is adjusted for model 1, smoking, alcohol, weight, height, diabetes, thiazide diuretics, PAS, and estrogen (in females). Model 3 is adjusted for model 2 plus eGFR and urine ACR.
b
P < .05.